VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.41 USD
0.00 (0.00%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $3.39 -0.02 (-0.59%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VTGN 3.41 0.00(0.00%)
Will VTGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTGN
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
Other News for VTGN
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
3 Stocks Under $15 That Could Make You a Millionaire
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
Vistagen Awarded Mental Health America?s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Biotech Alert: Searches spiking for these stocks today